Sleep Disorders News

Pediatric patients with severe obstructive sleep apnea and a vitamin D deficiency faced more severe sleep apnea vs. those without this deficiency, according to results published in JAMA Otolaryngology–Head & Neck Surgery.

Individuals with a moderate to high risk for obstructive sleep apnea, as measured via the STOP-Bang questionnaire, were more likely to experience suicidal ideations, plans and attempts, according to research conducted in South Korea.

Veterans with apnea-hypopnea index scores implying no sleep apnea or severe sleep apnea had higher all-cause mortality rates vs. those with mild/moderate sleep apnea, according to data published in Annals of the American Thoracic Society.

Among patients with obstructive sleep apnea, those treated with sleep surgery vs. CPAP had decreased odds for motor vehicle accident incidence, according to results published in Otolaryngology-Head and Neck Surgery.

Entering 2025, adults with moderate to severe obstructive sleep apnea and obesity have a new FDA-approved treatment option that takes the form of a GIP/GLP-1 dual agonist, according to a press release from Eli Lilly and Company.

The FDA approved the phase 2 Explore-OSA trial set to assess the highly selective aldosterone synthase inhibitor, lorundrostat, in adults with obstructive sleep apnea and hypertension, according to a press release.

The likelihood for obstructive sleep apnea went down by 74% among adults with optimal vs. insufficient healthy lifestyle behaviors, according to results published in BMC Pulmonary Medicine.

Healio Pulmonology has compiled the top news on sleep disorders posted in 2024.

The FDA has approved Zepbound (tirzepatide), a prescription medicine for adults with moderate to severe obstructive sleep apnea and obesity, Eli Lilly and Company announced ina press release.